Key result
The STOP-ACEi trial is designed to evaluate whether discontinuing ACEi/ARBs can improve or stabilize renal function at 3 years in 410 patients with advanced progressive chronic kidney disease.
Why the study?
Does discontinuation of ACEi/ARBs improve or stabilize renal function in patients with advanced progressive CKD?
Population
410 participants with advanced (Stage 4 or 5) progressive CKD receiving ACEi, ARBs or both
Comparison
Discontinue ACEi, ARB or combination of both vs Continue ACEi, ARB or combination of both
Design
Other, 1:1 ratio, open-label
Follow-up
3 years
Authors
Loading...
This trial design paper outlines the STOP-ACEi study, which will determine if withdrawing ACEi/ARB therapy improves renal function in advanced progressive CKD.
RCT (n=410)
Open-label
1:1
Yes
Does discontinuation of ACEi/ARBs improve or stabilize renal function in patients with advanced progressive CKD?
This trial design paper outlines the STOP-ACEi study, which will determine if withdrawing ACEi/ARB therapy improves renal function in advanced progressive CKD.
Bhandari et al. (2015) conducted an RCT in Advanced (Stage 4 or 5) progressive chronic kidney disease (n=410). Discontinuation of ACEi, ARB or combination of both vs. Continuation of ACEi, ARB or combination of both was evaluated on eGFR at 3 years. The STOP-ACEi trial is designed to evaluate whether discontinuing ACEi/ARBs can improve or stabilize renal function at 3 years in 410 patients with advanced progressive chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: